Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (51853)	2/17/2000 11:39:00 AM
From: Arcane Lore	Read Replies (1) \| Respond to of 122087

Aastrom Biosciences, Inc. Denies Fallacious Press Release PR Newswire - February 17, 2000 11:20 ANN ARBOR, Mich., Feb. 17 /PRNewswire/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported that its website has been corrupted by sabotage. A fallacious press release announcing that Aastrom was merging with Geron, Inc. was posted to the Aastrom website, apparently by a computer hacker. Aastrom stated that there is no truth to the merger announcement. The Company has alerted Nasdaq authorities and Geron to the violation and is investigating the matter further. "We are appalled by this ruthless attempt to manipulate markets and potentially harm the shareholders of both companies," said R. Douglas Armstrong, Ph.D., President and CEO of Aastrom. "While we have no idea how this occurred, we are currently investigating the security of the website. In the meantime, we apologize to our shareholders for any disruption in the trading of Aastrom's stock and wish to assure financial markets that we will work closely with the appropriate authorities to pursue those who are responsible." Aastrom Biosciences, Inc. is pioneering the development of proprietary clinical systems including the AastromReplicell(TM) System, a first of its kind product, to enable physicians and patients greater accessibility to cells used for therapy. Aastrom has received patents covering methods and devices for the ex vivo production of human stem and other types of cells, as well as for the genetic modification of stem cells. The AastromReplicell(TM) System is under development, and is not available for sale at this time in the U.S., except for research and investigational use. SOURCE Aastrom Biosciences, Inc. /Contact: Todd E. Simpson, VP Finance & Administration, CFO of Aastrom Biosciences, Inc., 734-930-5777 or Investor & Media: Francesca T. DeVellis of Feinstein Kean Healthcare, 617-577-8110/ marketwatch.newsalert.com